Disease Modifying Drugs for Alzheimer's Disease

Alzheimer's disease is linked to abnormal proteins in the brain called neurofibrillary tangles and amyloid plaques.  Aducanumab is the first approved medication as a disease modifying agent for Alzheimer's disease. Aducanumab reduces the amount of amyloid plaque in the brain.

Class Drugs

• Aducanumab

Class Mechanism of Action

Monoclonal antibody treatment that reduces amyloid plaques in the CNS

Class Application

Alzheimer's Disease

Class Adverse Effects

Cerebral edema

CNS microhemorrhages

Drug Table

Drug Name	Application	Comments	Image
Aducanumab	Alzheimer's Disease		"Ad" "Canoe" "Mob"